Scholars@Duke
Sanghee Hong

Sanghee Hong

Assistant Professor of Medicine
Medicine, Hematologic Malignancies and Cellular Therapy
sanghee.hong@duke.edu
2400 Pratt Street, Box 3961, Durham, NC 27710

Scholarly Works - Conferences

Impact of recipient sociodemographic factors on allogeneic transplant conditioning intensity and survival outcomes in myeloid malignancies: A secondary analysis of CIBMTR data

Conference Blood · November 3, 2025 AbstractIntroduction: Sociodemographic factors influence all aspects of the allogeneic hematopoietic cell transplantation (HCT) process. Th ... Full text Cite

Phase I trial of ruxolitinib plus fostamatinib for the treatment of steroid refractory chronic graft versus host disease

Conference Blood · November 3, 2025 AbstractBackground and Significance: Current therapies for steroid-refractory chronic graft versus host disease (SR-cGVHD) feature limited ... Full text Cite

Preliminary anti-leukemia activity from A phase 1 study of cln-049, a novel anti-FLT3 x anti-CD3 bispecific T-cell engager, in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS)

Conference Blood · November 3, 2025 AbstractBackground Common targets for T-cell–redirecting immunotherapies in AML and MDS have previously presented challenges. CLN-049 is a ... Full text Cite

Real-world survival outcomes with first-line venetoclax therapy in AML

Conference Blood · November 3, 2025 AbstractIntroduction: Venetoclax, a selective BCL-2 inhibitor combined with a hypomethylating agent (azacitidine or decitabine), has become ... Full text Cite

Automated identification and quantification of myeloblasts among myeloid lineage cells on bone marrow biopsy using deep learning aligns with hematopathologist readings in patients with Acute Myeloid Leukemia and high-risk myelodysplastic syndrome

Conference Blood · November 3, 2025 AbstractBackground: Assessing myeloblast counts in bone marrow biopsy (BMBx) and aspiration is essential for diagnosis and disease status e ... Full text Cite

Understanding Sociodemographic Barriers in Hematopoietic Stem Cell Transplantation Among Patients with Hematologic Malignancies: Insights from a North Carolina Cohort

Conference Blood · November 5, 2024 Background: Hematopoietic Stem Cell Transplantation (HCT) is a life-saving treatment for many patients with hematologic malignancies. Disparities persist across the transplant continuum. ... Full text Cite

Disparities in CAR-T Therapy Access and Outcomes: Variation in Referral Patterns for CAR-T Therapy in Patients with Newly Diagnosed Malignancies at an Academic Center in North Carolina

Conference Blood · November 5, 2024 Introduction: Chimeric Antigen Receptor (CAR)- T cell therapy has revolutionized the treatment of hematologic malignancies. However, access to CAR-T therapy remains limited, especially fo ... Full text Cite

Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States

Conference Blood · November 5, 2024 Background: Survivors of allogeneic hematopoietic cell transplantation (HCT) are at risk for treatment-related late effects. Published recommendations for screening/prevention of late com ... Full text Cite

Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States

Conference Blood · November 5, 2024 Background: Prior studies have reported variable adherence to screening/prevention guidelines from allogeneic hematopoietic cell transplant (HCT) survivors' perspective (Khera N et al. Bi ... Full text Cite